4503 logo
4503
Astellas Pharma

Intensifying Pricing Scrutiny Will Diminish Valuation Despite Pipeline Catalysts

AN
AnalystLowTarget
AnalystLowTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
12 Jun 25
Updated
23 Jul 25
AnalystLowTarget's Fair Value
JP¥1,300.00
21.6% overvalued intrinsic discount
23 Jul
JP¥1,580.50
Loading
1Y
-2.9%
7D
5.5%

Author's Valuation

JP¥1.3k

21.6% overvalued intrinsic discount

AnalystLowTarget Fair Value